ANI Pharmaceuticals Inc (ANIP) KPIs and segments
Close on Nov 16, 2026Market cap $1.63BP/E 15.1Yield –
KPIs & segments
Operating metrics and segments that drive ANI Pharmaceuticals's business
ANI Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rare Disease and Brands($M) | 165 | 128 | 144 | 129 | 117 | 94.1 | 107 | 65.6 | 59.2 | 62.6 | |||
Generics and Other($M) | 101 | 109 | 103 | 98.7 | 94.2 | 103 | 83.7 | 82.7 | 78.8 | 74.8 | |||
Earlier reporting (last reported 2024)2 | |||||||||||||
Rare Disease and Brands total net revenues($M) | 165 | 128 | 144 | 129 | 117 | 94.1 | 107 | 65.6 | 59.2 | 62.6 | |||
Rare Disease total net revenues($M) | 136 | 94.4 | 131 | 118 | 104 | 69.0 | 87.0 | 56.4 | 49.2 | 36.9 | 41.7 | 29.7 | |
Cortrophin Gel($M) | 117 | 75.1 | 111 | 102 | 81.6 | 52.9 | 59.4 | 52.6 | 49.2 | 36.9 | 41.7 | 29.7 | |
Generics and Other total net revenues($M) | 101 | 109 | 103 | 98.7 | 94.2 | 103 | 83.7 | 82.7 | 78.8 | 74.8 | |||
Generic pharmaceutical products($M) | 99.1 | 105 | 101 | 94.4 | 90.3 | 98.7 | 78.6 | 78.2 | 74.0 | 70.2 | 71.8 | 70.6 | |
ILUVIEN and YUTIQ($M) | 18.7 | 19.3 | 19.8 | 16.6 | 22.3 | 16.1 | 27.6 | 3.87 | 0 | 0 | 0 | 0 | |
Brand royalties and other revenues($M) | 17.7 | 21.5 | 0 | 0 | |||||||||
Brands($M) | 11.8 | 12.3 | 12.3 | 10.7 | 13.2 | 25.1 | 19.8 | 9.20 | 10.0 | 25.7 | |||
Unapproved Products($M) | 5.70 | 6.30 | 6.50 | 6 | 6.10 | 5.50 | 6 | 5.50 | 6.80 | 4.10 | 6 | 9.20 | |
Royalties and other pharmaceutical services($M) | 2.71 | 4.31 | 3.92 | 4.36 | 5.09 | 4.49 | 4.86 | 4.60 | |||||
Other generic revenues($M) | 1.61 | 3.82 | 3.92 | 4.36 | |||||||||
Earlier reporting (last reported 2024)2 | |||||||||||||
United States($M) | 182 | 147 | 138 | 137 | 132 | 132 | |||||||
International($M) | 8.17 | 1.22 | 0 | 0 | |||||||||
Earlier reporting (last reported 2024)1 | |||||||||||||
Rare Disease and Brands($M) | 52.3 | 36.3 | 49.0 | 41.7 | 29.5 | 21.1 | 28.6 | 5.42 | 15.3 | 23.1 | |||
Generics and Other($M) | 36.5 | 40.3 | 33.2 | 35.1 | 38.2 | 48.5 | 24.4 | 32.6 | 30.0 | 29.0 | |||
Rare Disease and Brands($M) | 117 | 94.3 | 102 | 89.5 | 85.8 | 67.5 | 73.6 | 45.1 | 43.5 | 50.3 | |||
Generics and Other($M) | 49.3 | 49.6 | 45.0 | 45.0 | 51.0 | 56.5 | 36.7 | 40.1 | 36.8 | 38.0 | |||
Rare Disease and Brands($M) | 52.3 | 36.3 | 49.0 | 41.7 | 29.5 | 21.1 | 28.6 | 5.42 | 15.3 | 23.1 | |||
Generics and Other($M) | 36.5 | 40.3 | 33.2 | 35.1 | 38.2 | 48.5 | 24.4 | 32.6 | 30.0 | 29.0 | |||
Earlier reporting (last reported 2024)2 | |||||||||||||
8 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-07.
See a number that looks wrong?